Title |
Analysis of clinical efficacy of CyberKnife® treatment for locally advanced pancreatic cancer
|
---|---|
Published in |
OncoTargets and therapy, June 2015
|
DOI | 10.2147/ott.s81939 |
Pubmed ID | |
Authors |
Yongchun Song, Zhiyong Yuan, Fengtong Li, Yang Dong, Hongqing Zhuang, Jingsheng Wang, Huaming Chen, Ping Wang |
Abstract |
To evaluate the efficacy and safety of CyberKnife(®) treatment for locally-advanced pancreatic cancer (LAPC). The efficacy of CyberKnife(®) treatment was analyzed in 59 LAPC patients treated between October 2006 and September 2014. The median tumor volume was 27.1 mL (13.0-125.145 mL). The median prescribed dose was 45 Gy (35-50 Gy), delivered in 5 fractions (3-8 fractions). The overall survival (OS) rates and freedom from local progression (FFLP) rates were estimated using the Kaplan-Meier survival curve. The median follow-up for all patients was 10.9 months (3.2-48.7 months) and 15.6 months (3.9-37.6 months) among surviving patients. The median OS was 12.5 months, and the 1-year and 2-year survival rates were 53.9% and 35.1%, respectively. The 1-year FFLP rate was 90.8% based on the computed tomography (CT) evaluation. Grade 1-2 acute and late-stage gastrointestinal (GI) reactions were observed in 61% of the patients. One patient experienced grade 3 toxicity. Excellent clinical efficacy was obtained after treatment of LAPC using CyberKnife(®), with minimal toxicity. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 31 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 5 | 16% |
Student > Ph. D. Student | 4 | 13% |
Researcher | 4 | 13% |
Student > Bachelor | 3 | 10% |
Professor | 2 | 6% |
Other | 6 | 19% |
Unknown | 7 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 48% |
Engineering | 2 | 6% |
Social Sciences | 2 | 6% |
Physics and Astronomy | 1 | 3% |
Unspecified | 1 | 3% |
Other | 0 | 0% |
Unknown | 10 | 32% |